SCYX (scynexis.com) Net Profit

SCYX (SCYNEXIS, Inc.) - company brandmark

SCYNEXIS, Inc. (SCYX) is attracting leading microbiologists to combat antibiotic resistance by creating an ethical scientific and clinical environment. Profits from the company's core operations reflect financial performance dynamics, where the value of -0.01 characterizes this level. The uniqueness of new antifungal molecules provides the firm with significant pricing power. The brand is currently expanding the global distribution of Brexafemme, strengthening strategic partnerships within the sector.

SCYX (SCYNEXIS, Inc.) Net Profit history from 07/04/2022 to 10/29/2026

Financial and market metric breakdowns for scynexis.com (SCYX)

- price and consensus price forecast:
Stock Quotes SCYNEXIS|SCYX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization SCYX|SCYX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share SCYNEXIS|SCYX - Book Capitalization|Market Capitalization to Book Value scynexis.com|SCYX - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Ratio SCYNEXIS, Inc.|SCYX - Long-Term Debt to Capital|Current Liabilities to Equity SCYNEXIS|SCYX - Company Aggregate Debts|Debts to Book Value SCYX|SCYX - Company Long-Term Debts|Company Current Liabilities SCYNEXIS|Intermediate Liquidity Ratio scynexis.com
- net income and valuation multiples indicators:
SCYX - Net Profit
Fundamental valuation:SCYX Scynexis
Brand item of scynexis.com

SCYNEXIS, Inc. (SCYX) specialization in combating infections requires high expenditures for laboratory environmental compliance and the implementation of filtration systems, which directly impacts final margins. By analyzing the company's net income, an investor sees the remaining funds after deducting all operating expenses and taxes, allowing for an assessment of the business model's real efficiency and the issuer's ability to generate free cash flow.

Direct competitors

Net Income Summit Pharma|MRNA (Moderna, Inc.) - Net Profit|Net Profit vaxcyte.com|Net Income TARS (Tarsus Pharmaceuticals, Inc.)|CRMD (CorMedix Inc) - Final Profit|Net Profit MCRB (Seres)|Net Financial Result Spero Pharma (SPRO)|ANTX - Company Net Income|PYPD (PolyPid Ltd.) - Company Profit|LSB: Net Profit|Profit After Tax ITRM (Iterum Therapeutics)|PHGE (BiomX Inc) - Net Profit|Company Net Income BioPharma Bio SNGX|Net Profit SXTP|Net Income Oragenics Inc. OGEN|Onconetix - Net Income|Profit After Payment of Taxes OPGN (OpGen Inc)